title: Does angiotensin-1 converting enzyme genotype influence motor or cognitive development after pre-term birth?
abstract: ABSTRACT : BACKGROUND : Raised activity of the renin-angiotensin system (RAS) may both amplify inflammatory and free radical responses and decrease tissue metabolic efficiency and thus enhance cerebral injury in the preterm infant. The angiotensin-converting enzyme (ACE) DD genotype is associated with raised ACE and RAS activity as well as potentially adverse stimuli such as inflammation. The DD genotype has been associated with neurological impairments in the elderly, and thus may be also associated with poorer motor or cognitive development amongst children born preterm prematurely. METHODS : The association of DD genotype with developmental progress amongst 176 Caucasian children born at less than 33 weeks gestation (median birthweight 1475 g, range 645-2480 g; gestation 30 weeks, range 22-32; 108 male) was examined at 2 and 5 1/2 years of age. Measured neuro-cognitive outcomes were cranial ultrasound abnormalities, cerebral palsy, disability, Griffiths Developmental Quotient [DQ] at 2 yrs, and General Cognitive Ability [British Ability Scales-11] and motor performance [ABC Movement], both performed at 5 1/2 yrs. All outcomes were correlated with ACE genotype. RESULTS : The DD genotype was not associated with lower developmental quotients even after accounting for important social variables. CONCLUSION : These data do not support either a role for ACE in the development of cognitive or motor function in surviving infants born preterm or inhibition of ACE as a neuroprotective therapy.
authors.affiliation: Neonatal Intensive Care Unit, St, Michael's Hospital, Bristol, UK. david.harding@bristol.ac.uk.
authors.forename: David R
authors.initials: DR
authors.lastname: Harding
authors.forename: Sukhbir
authors.initials: S
authors.lastname: Dhamrait
authors.forename: David
authors.initials: D
authors.lastname: Devadason
authors.forename: Steve E
authors.initials: SE
authors.lastname: Humphries
authors.forename: Andrew
authors.initials: A
authors.lastname: Whitelaw
authors.forename: Neil
authors.initials: N
authors.lastname: Marlow
authors.forename: Hugh E
authors.initials: HE
authors.lastname: Montgomery
references.citation: Nature. 2000 Feb 10;403(6770):614
references.pmid: 10688186
references.citation: J Pediatr. 2003 Dec;143(6):746-9
references.pmid: 14657821
references.citation: Neurosci Lett. 2000 Sep 1;290(3):177-80
references.pmid: 10963892
references.citation: Arch Dis Child Fetal Neonatal Ed. 1998 Jul;79(1):F4-11
references.pmid: 9797618
references.citation: Neuropediatrics. 1993 Oct;24(5):263-8
references.pmid: 8309515
references.citation: Circulation. 1999 Sep 21;100(12):1291-7
references.pmid: 10491373
references.citation: Lancet. 1999 May 15;353(9165):1653-7
references.pmid: 10335784
references.citation: J Neuropathol Exp Neurol. 1997 Mar;56(3):219-35
references.pmid: 9056536
references.citation: Semin Neonatol. 2000 Feb;5(1):3-16
references.pmid: 10802746
references.citation: Dev Med Child Neurol. 1998 Oct;40(10):652-60
references.pmid: 9851233
references.citation: Am J Obstet Gynecol. 1997 Jul;177(1):19-26
references.pmid: 9240577
references.citation: Biochem J. 1993 Feb 15;290 ( Pt 1):33-40
references.pmid: 8382480
references.citation: Neuropeptides. 2001 Feb;35(1):65-9
references.pmid: 11346312
references.citation: Arch Neurol. 2000 Feb;57(2):210-4
references.pmid: 10681079
references.citation: Neurosci Lett. 1999 May 28;267(2):97-100
references.pmid: 10400221
references.citation: Eur J Pharmacol. 1999 May 28;373(1):21-33
references.pmid: 10408248
references.citation: N Engl J Med. 2000 Aug 10;343 (6):378-84
references.pmid: 10933736
references.citation: Neurology. 2004 Oct 12;63(7):1324-5
references.pmid: 15477567
references.citation: Int J Dev Neurosci. 2004 Nov;22(7):475-84
references.pmid: 15465277
references.citation: J Clin Invest. 1990 Oct;86(4):1343-6
references.pmid: 1976655